Edition:
United Kingdom

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Select Market

11.53USD
23 Aug 2019
Change (% chg)

$-0.28 (-2.37%)
Prev Close
$11.81
Open
$12.02
Day's High
$12.02
Day's Low
$11.43
Volume
20,369
Avg. Vol
13,046
52-wk High
$25.00
52-wk Low
$11.43

Latest Key Developments (Source: Significant Developments)

Cellular Biomedicine Group Files For Mixed Shelf Of Up To $200 Million
Friday, 5 Jul 2019 

July 5 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING.  Full Article

Cellular Biomedicine Group Reports First Quarter 2019 Results And Highlights Operational Progress
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP REPORTS FIRST QUARTER 2019 RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.CELLULAR BIOMEDICINE GROUP INC - QTRLY LOSS PER SHARE $0.51; ENDED QUARTER WITH $62 MILLION IN CASH.  Full Article

Cellular Biomedicine Group Announces Pricing Of Public Offering Of Common Stock
Thursday, 21 Mar 2019 

March 21 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 1.03 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.  Full Article

Cellular Biomedicine Group Announces Proposed Follow-On Offering Of Common Stock
Wednesday, 20 Mar 2019 

Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP ANNOUNCES PROPOSED FOLLOW-ON OFFERING OF COMMON STOCK.CELLULAR BIOMEDICINE GROUP INC - ALL OF SHARES IN OFFERING ARE TO BE SOLD BY CBMG.  Full Article

Cellular Biomedicine Says Cash, Cash Equivalents And Marketable Securities As Of Dec 31, 2018 Were $52.8 Mln
Wednesday, 20 Feb 2019 

Feb 19 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.CELLULAR BIOMEDICINE -CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DEC 31, 2018 WERE $52.8 MILLION,COMPARED TO $21.6 MILLION AS OF DEC 31, 2017.  Full Article

Cellular Biomedicine Says Extended Implementation Period Of 2018 Repurchase Program For Another Three Months Or Until March 31, 2019
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP INC - EXTENDED IMPLEMENTATION PERIOD OF 2018 REPURCHASE PROGRAM FOR ANOTHER THREE MONTHS, OR UNTIL MARCH 31, 2019.  Full Article

Cellular Biomedicine Q3 Non-GAAP Loss Per Share $0.56
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP REPORTS THIRD QUARTER FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q3 NON-GAAP LOSS PER SHARE $0.56.Q3 LOSS PER SHARE $0.72.Q3 EARNINGS PER SHARE VIEW $-0.52 -- THOMSON REUTERS I/B/E/S.  Full Article

Cellular Biomedicine Group Reports Qtrly Loss Per Share $0.53
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP REPORTS SECOND QUARTER AND FIRST HALF 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.QTRLY LOSS PER SHARE $0.53.QTRLY REVENUE $77,313 VERSUS $62,914.CASH AND CASH EQUIVALENTS AT END OF PERIOD $24.8 MILLION COMPARED WITH $21.6 MILLION ON DEC 31, 2017.  Full Article

Cellular Biomedicine Announces Positive Clinical Data Of Knee Osteoarthritis China Phase I Trial
Friday, 16 Mar 2018 

March 16 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP ANNOUNCES POSITIVE 48-WEEK CLINICAL DATA OF ALLOJOIN™ HUMAN ADIPOSE-DERIVED MESENCHYMAL PROGENITOR CELL (HAMPC) KNEE OSTEOARTHRITIS (KOA) CHINA PHASE I TRIAL.CELLULAR BIOMEDICINE GROUP - STUDY SHOWED ALLOJOIN TO HAVE GOOD SAFETY TOLERANCE AND EARLY SIGNS OF EFFICACY IN PREVENTING CARTILAGE DETERIORATION.CELLULAR BIOMEDICINE - PRIMARY END POINT SHOWED A SIGNIFICANT IMPROVEMENT AT 12 WEEKS POST ALLOJOIN CELL THERAPY, CONTINUED IMPROVEMENT AT 48 WEEKS.CELLULAR BIOMEDICINE - SECONDARY END POINT SHOWED INCREASED TENDENCY VERSUS THAT AT BASELINE 0 WEEKS, VERSUS NORMAL CARTILAGE DETERIORATION AS RESULT OF AGING.CELLULAR BIOMEDICINE - DE-PRIORITIZING U.S. ALLOJOIN OPERATION & CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE PROJECT TERMINATED, EFFECTIVE MARCH 14.CELLULAR BIOMEDICINE - COMMON SIDE EFFECTS WERE TEMPORARY LOCAL REACTIONS INCLUDING SORENESS, SWELLING AT INJECTION SITE IN STUDY.CELLULAR BIOMEDICINE GROUP INC - TO DATE, NO SERIOUS ADVERSE EVENTS RELATED TO ALLOJOIN THERAPY HAVE BEEN REPORTED.CELLULAR BIOMEDICINE- 2 PATIENTS WHO UNDERWENT ONE DOSE OF INJECTIONS DROPPED OUT OF STUDY AS THEIR KNEE JOINTS WERE MORE PAINFUL AFTER INJECTION.  Full Article

Cellular Biomedicine Group Reports Full-Year 2017 Financial Results And Recent Operational Progress
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP REPORTS FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.CELLULAR BIOMEDICINE GROUP INC - HAD WORKING CAPITAL OF $20.9 MILLION AS OF DEC 31, 2017 COMPARED TO $38.3 MILLION AS OF DEC 31, 2016.  Full Article